A Phase 1 Dose finding study of lutetium (177Lu)-lilotomab satetraxetan (Betalutin®) in patients with relapsed/refractory, diffuse large B-cell lymphoma, not eligible for autologous stem cell transplant
Sonstige - Therapieart: palliativ